Physician profile
David M Wolfson
NPI 1861596041
$16,435.51
in general payments reported to CMS, 2019-2025
27 companies · $2,792 in 2025
The $2,792 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,835 · 2020: $814 · 2021: $3,149 · 2022: $2,368 · 2023: $2,125 · 2024: $3,353 · 2025: $2,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,093 · Education: $137 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,092.50 |
| Education | $136.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,670.01 | 2019-2025 | Rinvoq, Linzess, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,542.46 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Redhill Biopharma INC. | $1,675.11 | 2020-2022 | |
| Pfizer INC. | $1,327.04 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $777.71 | 2020-2025 | Linzess |
| Phathom Pharmaceuticals, INC. | $551.90 | 2023-2025 | Voquezna |
| Gilead Sciences, INC. | $507.87 | 2019-2022 | |
| Ardelyx, INC. | $462.45 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $456.00 | 2019-2022 | |
| Janssen Biotech, INC. | $451.36 | 2023-2025 | Tremfya, Stelara |
| Evoke Pharma, INC. | $364.58 | 2020-2025 | |
| Madrigal Pharmaceuticals | $339.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $338.48 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $305.27 | 2023-2025 | Dupixent |
| Concordia Pharmaceuticals INC. | $121.77 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $105.48 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $96.43 | 2022 | |
| Intra-Sana Laboratories | $67.18 | 2021-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Ferring Pharmaceuticals INC. | $40.52 | 2019-2022 | |
| Daiichi Sankyo INC. | $39.88 | 2019-2020 | |
| Exact Sciences Corporation | $39.47 | 2024 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $36.04 | 2021 | |
| Celltrion USA INC. | $29.69 | 2024 | Zymfentra |
| Allergan, INC. | $26.03 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $23.66 | 2024 | |
| Nestle Healthcare Nutrition INC. | $22.79 | 2023 | |
| W. L. Gore & Associates, INC. | $17.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wolfson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.